Dupilumab (Asthma) - Forecast and Market Analysis to 2023

Dupilumab (Asthma) - Forecast and Market Analysis to 2023 is a new market research publication announced by Reportstack. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Dupilumab, which is currently in Phase III of development for eosinophilic asthma by Regeneron and Sanofi, is a fully-humanized mAb against the interleukin-4 receptor a subunit (IL-4-Ra) that inhibits both the IL-4 and IL-13 signaling pathways. The similarities in activity between IL-13 and IL-4 in asthma pathogenesis have been established (Steinke et al., 2001; Wong et al., 2001). IL-4 is functionally similar to IL-13, and is present in increased levels in the sputum and bronchial tissue of asthmatic patients. It seems plausible that an agent that inhibits the activity of both IL-4 and IL-13 would be more effective (Wong et al., 2001). Therefore, dupilumab could have a ripple effect on the sales of IL-13 inhibitors, lebrikizumab, and tralokinumab.

Scope

- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Dupilumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Dupilumab for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Dupilumab performance
- Obtain sales forecast for Dupilumab from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

To access full report with TOC, please visit Dupilumab (Asthma) - Forecast and Market Analysis to 2023.